Patient Selection Factors for Stereotactic Body Radiotherapy and Radioembolization for Hepatic MetastasesTE Schefter*
Department of Radiation Oncology, University of Colorado School of Medicine, 1665 Aurora Ct, Suite 1032 MS F-706, Aurora, CO 80045, USA
- Corresponding Author:
- TE Schefter
Department of Radiation Oncology
University of Colorado School of Medicine1665 Aurora Ct
Suite 1032 MS F-706, Aurora, CO 80045, USA
E-mail: Tracey. [email protected]
Received Date: June 28, 2011; Accepted Date: December 04, 2011; Published Date: December 06, 2011
Citation: Schefter TE (2011) Patient Selection Factors for Stereotactic Body Radiotherapy and Radioembolization for Hepatic Metastases. J Nucl Med Radiat Ther 2:119. doi: 10.4172/2155-9619.1000119
Copyright: © 2011 Schefter TE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Liver metastases are a common source of morbidity and mortality. Despite significant improvements in outcome with systemic therapy in recent years, it is infrequent that liver metastases or sites of macrometastatic disease are controlled permanently. Furthermore, most liver metastases are not amenable to what is considered the gold standard locally ablative therapy, surgical resection and consequently there has been a surge in interest in non surgical ablative therapies. Review of patient selection factors for two such liver directed radiation therapies, radioembolization and stereotactic body radiation therapy (SBRT) will be addressed.